tebipenem and avibactam

tebipenem has been researched along with avibactam* in 5 studies

Other Studies

5 other study(ies) available for tebipenem and avibactam

ArticleYear
Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection.
    Antimicrobial agents and chemotherapy, 2023, 02-16, Volume: 67, Issue:2

    The combination of the β-lactam tebipenem and the β-lactamase inhibitor avibactam shows potent bactericidal activity against Mycobacterium abscessus

    Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Lung; Mice; Microbial Sensitivity Tests; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous

2023
Impact of acquired broad-spectrum β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam β-lactamase inhibitors in
    Antimicrobial agents and chemotherapy, 2023, 10-18, Volume: 67, Issue:10

    The impact of β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) and other carbapenem molecules was evaluated in

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Escherichia coli; Meropenem; Microbial Sensitivity Tests

2023
The
    Antimicrobial agents and chemotherapy, 2023, 10-18, Volume: 67, Issue:10

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Drug Combinations; Imipenem; Microbial Sensitivity Tests; Mycobacterium abscessus

2023
Strongly Bactericidal All-Oral β-Lactam Combinations for the Treatment of Mycobacterium abscessus Lung Disease.
    Antimicrobial agents and chemotherapy, 2022, 09-20, Volume: 66, Issue:9

    Bioactive forms of oral β-lactams were screened

    Topics: Amoxicillin; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Cefuroxime; Humans; Lactams; Lung Diseases; Microbial Sensitivity Tests; Mycobacterium abscessus

2022
Combinations of avibactam and carbapenems exhibit enhanced potencies against drug-resistant Mycobacterium abscessus.
    Future microbiology, 2017, Volume: 12

    The objective of this study was to assess if avibactam, a new β-lactamase inhibitor, can restore the potency of carbapenems, a sub-class of β-lactams, against Mycobacterium abscessus clinical isolates.. 28 M. abscessus clinical isolates that are resistant to multiple drugs currently used to treat its infection were included. MIC of carbapenems alone and in combination with avibactam against these strains were determined.. Tebipenem, an oral carbapenem, and ertapenem and panipenem exhibited the greatest shift in MIC when supplemented with avibactam.. Avibactam restores MICs of tebipenem, ertapenem and panipenem against M. abscessus to therapeutically achievable concentrations and raises the possibility of usefulness of these carbapenems to treat drug-resistant M. abscessus infections.

    Topics: Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactams; Carbapenems; Drug Resistance, Multiple, Bacterial; Ertapenem; Microbial Sensitivity Tests; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous; Thienamycins

2017